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Abstract: Systemic inflammatory response was reported to be a poor prognostic factor in several malignancies. An 
inexpensive and readily available laboratory tool, neutrophil to lymphocyte ratio (NLR), can be easily obtained from 
differential blood counts. Current evidence suggests that a baseline NLR may predict the long-term survival results of 
patients with lymphoproliferative diseases (especially diffuse large B-cell lymphoma). The relationship between systemic 
inflammation and cancer, and the usefulness of NLR in hematological malignancies will be disscussed in this 
comprehensive review.  
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INTRODUCTION 
Neutrophil to lymphocyte ratio (NLR),	   calculated 
from complete blood count with differential,	  may reflect 
and clarify the immune response in systemic 
inflammatory states [1]. NLR has been reported as an 
independent prognostic marker in solid [2] and 
hematological malignancies [3]. However, the number 
of studies about the use of NLR on the long-term 
results of hematological malignancies are quite a few 
when compared to those carried out with solid tumors. 
In this review, the basic mechanisms of inflammation, 
cancer development, and their relationship between 
NLR will be discussed. Additionally, the clinical use of 
NLR in hematological malignancies including classical 
Hodgkin lymphoma (HL), diffuse large B cell lymphoma 
(DLBCL), multiple myeloma (MM), and finally 
peripheral T-cell lymphoma will be reported in the light 
of current medical literature.  
CANCER AND INFLAMMATION 
A high NLR is associated with adverse outcomes in 
non-malignant conditions such as chronic inflammation 
in ischemic heart diseases [4], hepatic cirrhosis [5], and 
ulcerative colitis [6]. From this perspective, some 
researchers have demonstrated a positive correlation 
with NLR and known markers of systemic inflammation 
(i.e. erythrocyte sedimentation rate, C-reactive protein 
(CRP), fibrinogen) [1].  
Cancer-related systemic inflammatory response can 
up regulate cytokines, chemokines and other 
inflammatory mediators [7]. About 25% of cancers are  
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associated with chronic inflammation [8, 9]. Although 
the exact mechanism between inflammation and 
cancer remains unclear, two main factors are 
suggested: “extrinsic factors” that cause an ongoing 
chronic inflammation, and “intrinsic factors” that alters 
the expression of inflammation-related pathways via 
oncogenes and/or tumor suppressor genes [8].  
Tumor necrosis factor-alpha (TNF-α), interleukin 
(IL)-6 and IL-1 are the most commonly released 
inflammatory cytokines in the tumor microenvironment 
[7]. Plasma levels of TNF-α are elevated in patients 
with advanced cancer [10]. TNF-α produced either by 
host cells or malignant cells directly activate oncogens 
and DNA damage, which in turn may contribute to an 
increased propensity for metastasis activity. One of its 
receptor, TNF receptor 2, is generally found on the 
recruited leukocytes [11].  
Suppressed T-cell activity by neutrophils or 
immature myeloid cells, called myeloid-derived 
supressor cells (MDSCs), was linked to immune 
deregulation in advanced cancer patients. The major 
cause of severe systemic T-cell supression was 
thought to be induced by a neutrophil-derived effector 
molecule, H2O2 [12]. IL-8 induces exocytosis of 
arginase-1 by neutrophils in non-small cell lung cancer 
cell lines which inhibits T-cell proliferation by degrading 
extracellular arginine [13]. Arginase production from 
CD11b+, CD14-, CD15+ cells with polymorphonuclear 
morphology in metastatic renal cell carcinoma patients 
have been shown to be a mechanism of tumor evasion 
[14]. Matrix metalloproteinase (MMP)- 9 predominantly 
expressed by bone marrow-derived CD-45 positive 
leukocytes contributes to the formation of a mature 
vasculature, resulting in angiogenesis and tumor 
progression in a murine neuroblastoma model [15]. 
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More recently, upregulated MMP-2 expression by 
ovarian cancer cells has been associated with the initial 
steps of metastasis [16]. CXCL1/macrophage 
inflammatory protein-2 (MIP-2) leads to accululation of 
murine neutrophils that, in turn, increase the production 
of vascular endothelial growth factor-A, resulting in 
angiogenesis in vivo [17].  
Taken together, development of cancer still remains 
to be explained in terms of inflammation. However, 
there are growing evidence-based data supporting the 
critical role of cancer-related systemic inflammation on 
tumor cell survival and proliferation, angiogenesis, 
tumor invasion and progression.  
WHY DO WE NEED A NOVEL PROGNOSTIC 
MARKER? 
Prognostic models for hematologic malignancies 
that are inexpensive, readily available, easy to perform 
and interpret are needed in clinical practice, especially 
in resource-poor countries. Besides the solid tumors, 
there is a growing interest about the use of NLR in an 
attempt to predict the long-term results of 
hematological malignancies. The core studies about 
this recent issue are listed in Table 1. 
CLASSICAL HODGKIN LYMPHOMA 
It has long been known that the baseline 
lymphocyte count has a prognostic role in classic 
Hodgkin lymphoma (cHL). Lymphopenia (<600 cells/µL 
or <8% of the white blood cell count) is related to 
adverse survival outcome [18], as well as tumor-
infiltrating lymphocytes and tumor-infiltrating 
macrophages that constitute tumor microenvironment 
[19, 20].  
The accumulation of neutrophils is thought to be 
related with increased cytokin levels, especially IL-8 
[21]. By combined isotopic in situ hybridization and 
advanced immunohistologic studies, IL-8 expression is 
Table 1: Core Clinical Studies About the Use of Neutrophil-to-Lymphocyte Ratio in Several Hematological 
Malignancies for Predicting Long-Term Results 
References Disease n NLR Cut off NLR  
Median 
Follow-Up Clinical Value 
Porrata et al. [3] DLBCL 255 NS 3.5 59.1 months 
Patients with a NLR ≥3.5 at diagnosis experienced inferior 
5-year OS and PFS compared with patients with a NLR 
<3.5. A higher NLR at diagnosis was also associated with 
higher IPI scores, B-symptoms and LDH levels.   
Troppan et al. [27] DLBCL 290 NS 4 33.5 months NLR ≥4 was associated with worse OS. 
" " " " 1.8 " NLR ≥1.8 was associated with shorter DFS. 
Keam et al. [28] DLBCL 447 2.54 (0.03-94.0) 3 59.0 months 
A pre-NLR ≥ 3 was independently related with poor OS 
and PFS in newly-diagnosed DLBCL patients treated with 
R-CHOP. Among patients who had an initially pre-NLR 
≥3, those whose NLR decreased to <3 after R-CHOP had 
significantly better OS and PFS than patients whose NLR 
remained high after R-CHOP.  
Ho et al. [30] DLBCL 148 4.25 ± 3.63 4.35 53.28 months NLR was found to be a prognostic tool of 5-year OS and 5-year PFS.  
Melchardt et al. [31] DLBCL 515 NA 5.54 53 months NLR did not correlate with survival. 
Koh YW et al. [23] cHL 312 3.8 (0.09-29.67) 4.3 64 months 
Patients with a NLR ≥4.3 at diagnosis experienced inferior 
5-year OS compared with patients with a NLR <4.3, but 
did not differ in terms of EFS.  
Kelkitli et al. [37] MM 151 2.79 ± 1.82 2 41 months 
Patients with a NLR ≥2 at diagnosis experienced inferior 
5-year OS and EFS compared with patients with a NLR 
<2.  
Romano et al. [38] MM 309 1.9 (0.4-15.9) 2 NS 
In the era of novel anti-myeloma agents, patients with a 
NLR ≥2 at diagnosis experienced inferior 5-year OS and 
PFS compared with patients with a NLR <2.   
Beltran et al. [39] PTCL-U 83 2.5 (0.3-99) 4 NS NLR ≥4 was associated with worse OS. 
Abbreviations: NLR: Neutrophil to lymphocyte ratio; n: Number of patients; DLBCL: Diffuse large B-cell lymphoma; cHL: Classical Hodgkin lymphoma; MM: Multiple 
myeloma; PTCL-U: Peripheral T-cell lymphoma unspecified; OS:  Overall survival; DFS: Disease-free survival; PFS: Progression-free survival; EFS: Event-free 
survival; IPI: International prognostic index; LDH: Lactate dehydrogenase; R-CHOP: Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; NS: Not 
stated, NA: Not available.  
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largely confined to reactive infiltrate cells and less 
frequently to Hodgkin and Reed-Stenberg cells, 
particularly in the nodular sclerosing subtype [22].  
We could find only one study in the medical 
literature about the use of NLR in cHL [23]. In this 
retrospective analysis, 312 patients with cHL were 
enrolled and the median follow-up after diagnosis and 
NLR value were, 64 months and 3.8, respectively. 
Patients with NLR ≥4.3 at diagnosis were found to be 
more likely to present with anemia, lymphopenia, 
hypoalbuminemia, abnormal lactate dehydrogenase 
(LDH), presence of B symptoms, and advanced 
disease stage. In contrast, NLR did not corralete with 
age, treatment modality, chemoteraphy regimen or the 
presence of Epstein-Barr virus. The patients with NLR 
≥4.3 had significantly lower 5-year estimated overall 
survival (OS) than those patients with NLR <4 (80.3% 
vs. 91.9%, p= < .001), but the groups did not differ in 
terms of event-free survival (EFS). The OS advantage 
was detected in only advanced-stage (stage IV) 
subgroups. In multivariate analyses NLR ≥4 was 
detected as an independent prognostic factor.  
International Prognostic Score (IPS) is also an 
independent predictor and is used for risk stratification 
in HL [18]. Therefore, Koh et al. have combined NLR 
and IPS, “IPS-NLR”. In low-risk IPS patients (IPS <4), 
the patients with NLR ≥4 presented with worse OS than 
those with NLR <4. This difference was not noted in 
high IPS risk patients (IPS= 4). Nodular sclerosing was 
found to be the most common (56.7%) subtype in the 
aforementioned cohort. When the statistical analyses 
were reanalysed in noduler sclerosing subgroup alone, 
the predictive impact of a NLR value of ≥ 4 were 
ongoing in terms of OS (but not for EFS) [23].  
DIFFUSE LARGE B CELL LYMPHOMA 
NLR is most frequently investigated in patients with 
diffuse large B-cell leymphoma (DLBCL). Besides 
direct apoptosis against lymphoma cells and antibody-
dependent cell cytotoxicity, another possible 
mechanism of action of rituximab is to target the 
inflammatory component of the tumor by causing 
neutropenia [24] and direct inhibition of signal 
transducer and activator of transcription-3 [25] and 
nuclear factor kappa-B [26].  
Firstly, Porrata et al. have investigated the possible 
predictive effect of NLR on survival rates of 255 DLBCL 
patients. With a median follow-up of 4 years, DLBCL 
patients with a NLR < 3.5 at diagnosis experienced a 
superior OS (87% vs. 56%, respectively) and 
progression-free survival (PFS, 72% vs. 45%, 
respectively) compared to those patients with a NLR ≥ 
3.5 at diagnosis. Multivariate analysis showed NLR to 
be an independent prognostic factor for OS and PFS. 
Extranodal disease, number of cycles of rituximab, 
cyclophosphamide, doxorubicin, vincristine, 
prednisolone (R-CHOP), post-chemotherapy radiation 
therapy, and the reasons for post-chemotherapy 
radiation therapy was similar in both groups. A higher 
NLR was also associated with higher IPI scores and B-
symptoms. The authors have also identified a positive 
correlation between NLR at diagnosis and LDH levels. 
NLR at diagnosis was an independent predictive factor 
besides stage for LDH production [3].  
Afterwards, Troppan et al. have demonstrated that a 
high derived NLR at diagnosis of DLBCL significantly 
associated with poor outcome in terms of OS and 
disease-free survival (DFS) [27]. Similarly, a pre-NLR ≥ 
3 was independently related with poor OS and PFS in 
newly-diagnosed DLBCL patients treated with R-
CHOP. In patients with high pre-NLR, reduction of the 
post-NLR < 3 after R-CHOP treatment was correlated 
with improved survival. When adding pre-NLR to the 
IPI score, survival prediction and risk stratification were 
improved. Moreover, low pre-NLR (< 3) was associated 
with a higher number of peripheral CD19+ lymphocytes 
and natural killer cells [28]. Although, these two studies 
[27, 28] were retrospective, they have had large 
number of DLBCL patients (290 and 447, respectively).  
Chang et al. [29] have compared peripheral blood 
samples of 77 patients with DLBCL and 30 healthy 
controls. The patients with DLBCL had significantly 
higher percentages of neutrophils, and lower 
percentages of lymphocytes compared to control 
patients. In univariate analysis, high neutrophil counts 
(≥6,000/µL) were found to be a poor prognostic factor 
for survival in addition to high IPI scores. And finally, in 
a retrospective analysis including 148 newly-diagnosed 
DLBCL patients, the NLR was found to be a prognostic 
tool of 5-year OS and 5-year PFS by univariate 
analyses [30].  
In contrast to these hopeful results, in a very recent 
retrospective analysis including 515 patients with 
DLBCL, NLR did not correlate with survival [31], as well 
as high gamma-glutamyl transferase levels, and 
platelet to lymphocyte ratio. In multivariate analyses, 
anemia, high C-reactive protein and high bilirubin levels 
had an independent prognostic value for survival in 
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addition to the National Comprehensive Cancer 
Network-International Prognostic Index (NCCN-IPI) 
score.  
MULTIPLE MYELOMA  
MM is a clonal disorder characterized by the 
proliferation of plasma cells and their accumulation 
within the bone marrow. Age, performance status, 
serum β2-microglobulin level, the hemoglobin level, the 
presence of circulating plasma cells, plasmablastic 
morphology, the plasma cell proliferation status 
(detected either by plasma cell labeling index or flow 
cytometry) are well-known prognostic factors in MM. 
Additionally, in some reports, a low platelet count, 
hypercalcemia, and a low serum albumin level have 
associated with poor prognosis [32]. Given the disease 
heterogenity and the dynamic process of the disorder, 
it is sometimes not possible to predict the prognosis of 
patients exactly.  
International Staging System (ISS) is a worldwide-
accepted classification system based on serum 
albumin and β2-microglobulin levels [33]. The patients 
should be divided into 3 subgroups according to the 
ISS, with median survival varying from 62 months 
(stage I) to 29 months (stage III). Although ISS is 
inexpensive and readily available, it does not take into 
account the cytogenetic profile of the patients and the 
role of bone marrow microenvironment. Additionally it 
was validated retrospectively on patients treated prior 
to the advent of novel anti-myeloma agents including 
proteasome inhibitors (bortezomib, carfilzomib), 
immunomodulators (lenalidomide, pomalidomide), or 
their combinations. Therefore, the investigators have 
tried to enhance the performance of the ISS by adding 
other soluble markers or genetic risk features [34-36].  
In a retrospective analysis including 151 patients 
with MM [37], mean NLR was significantly higher in 
patients with MM than age- and gender- matched 
healthy controls (2.79 ± 1.82 vs. 1.9 ± 0.61). Patients 
with NLR ≥2 had significantly higher serum CRP levels, 
more frequent renal impairment, and more advanced 
ISS stage. In addition, NLR is independently 
associated with long-term results of MM patients. After 
a 41 months follow-up, 5-year estimated OS and event-
free survival (EFS) rates were significantly lower in 
patients with a NLR ≥2 (42.4% vs. 87.5%) compared to 
those with a NLR <2 (41.8% vs. 88.4%). On the other 
hand, mean lymphocyte counts, bone marrow 
infiltration ratio by plasma cells, treatment regimens, 
and autologous stem cell transplantation rates were 
found to be similar between the groups in terms of 
NLR. A major limitation of this retrospective analysis 
was that the limited use of initial cytogenetic analysis 
which is a prognostic parameter that affects long-term 
survival rates of MM patients [34-36]. Cytogenetic data 
were available for only 34.4% of the cases. Among 
these patients 44.2% of them had cytogenetic 
abnormalities and the most frequent (30.7%) adverse 
chromosomal abnormality was reported as del(13q) 
[37].  
More recently, Romano et al. [38] have investigated 
the predictive value of initial NLR in 309 newly 
diagnosed MM patients whom treated upfront with 
novel agents in a retrospective fashion. 37% of their 
cohort received high-dose therapy followed by 
autologous stem cell transplantation (ASCT) as 
consolidation. A NLR ≥2 was correlated with inferior 
estimated PFS and OS rates among non-elderly (<65 
years) MM patients in all ISS stages and those patients 
underwent ASCT. In contrast, NLR values did not add 
any significant impact on long-term survival parameters 
for elderly MM patients. Despite the upfront 
administration of novel and more efficient therapies, the 
results were found to be less promising. Romano et al. 
have reported their 5-year estimated PFS and OS 
rates, respectively, 18.2% and 36.4% for MM patients 
with NLR ≥2 versus 25.5% and 66.6% for patients with 
NLR <2.  
The authors have also provided a new model 
including both NLR and ISS staging, “ISS-NLR”, and 
they have limited the deeper analyses for non-elderly 
MM patients. They have reported that NLR-ISS was 
able to predict PFS and OS rates in very-low, standard, 
and very-high risk subgroups, while ISS only was 
unable. This new model may provide a cost-effective 
and sustainable prognostic parameter in newly 
diagnosed MM patients especially in countries where 
cytogenetic analyses are not available in daily clinical 
practice. Additionally, a higher NLR did not correlate 
with the type of induction regimen (based on 
proteasome inhibitors, immunomodulator agents, or 
combined) or an adverse karyotype. The authors have 
also stated that initial cytogenetic analyses were 
available for 54% of patients and adverse 
chromosomal abnormalities were observed in 17% of 
the cases (detailed data not presented) [38].  
As a result, novel and available predictors of long-
term survival in newly diagnosed MM patients are 
encouraged in order to better evaluate the risk profile of 
these patients in the era of novel anti-myeloma agents.  
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PERIPHERAL T-CELL LYMPHOMA  
Recently, Beltran et al. retrospectively evaluated 83 
peripheral T-cell lymphoma unspecified (PTCL-U) 
patients in terms of NLR [39]. In multivariate analyses, 
a NLR ≥4 was independently associated with worse OS 
after adjustment for the IPI score and the Prognostic 
Index for PTCLU (PIT) score.  
CONCLUSION  
NLR, seems to be a promising prosnostic tool for 
predicting long-term results in lymphoproliferative 
hematologic malignancies. Further and comprehensive 
prospective studies are needed in order to better 
understand and interpret the exact role of NLR in these 
complex disorders. These efforts will also provide 
further therapeutic insights for clinicians.  
REFERENCES 
[1] Zahorec R. Ratio of neutrophil to lymphocyte counts--rapid 
and simple parameter of systemic inflammation and stress in 
critically ill. Bratisl Lek Listy 2001; 102: 5-14. 
[2] Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic 
Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A 
Systematic Review and Meta-Analysis. J Natl Cancer Inst 
2014; 106: dju124. 
http://dx.doi.org/10.1093/jnci/dju124 
[3] Porrata LF, Ristow K, Habermann T, Inwards DJ, Micallef IN, 
Markovic SN. Predicting survival for diffuse large B-cell 
lymphoma patients using baseline neutrophil/lymphocyte 
ratio. Am J Hematol 2010; 85: 896-9. 
http://dx.doi.org/10.1002/ajh.21849 
[4] Park JJ, Jang HJ, Oh IY, et al. Prognostic value of neutrophil 
to lymphocyte ratio in patients presenting with ST-elevation 
myocardial infarction undergoing primary percutaneous 
coronary intervention. Am J Cardiol 2013; 111: 636-42. 
http://dx.doi.org/10.1016/j.amjcard.2012.11.012 
[5] Kwon JH, Jang JW, Kim YW, et al. The usefulness of C-
reactive protein and neutrophil-to-lymphocyte ratio for 
predicting the outcome in hospitalized patients with liver 
cirrhosis. BMC Gastroenterol 2015; 15: 146. 
http://dx.doi.org/10.1186/s12876-015-0378-z 
[6] Posul E, Yilmaz B, Aktas G, Kurt M. Does neutrophil-to-
lymphocyte ratio predict active ulcerative colitis? Wien Klin 
Wochenschr 2015; 127: 262-5. 
http://dx.doi.org/10.1007/s00508-014-0683-5 
[7] Balkwill FR, Mantovani A. Cancer-related inflammation: 
common themes and therapeutic opportunities. Semin 
Cancer Biol 2012; 22: 33-40. 
http://dx.doi.org/10.1016/j.semcancer.2011.12.005 
[8] Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related 
inflammation. Nature 2008; 454: 436-44. 
http://dx.doi.org/10.1038/nature07205 
[9] Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, 
and cancer. Cell 2010; 140: 883-99. 
http://dx.doi.org/10.1016/j.cell.2010.01.025 
[10] Balkwill F. Tumour necrosis factor and cancer. Nat Rev 
Cancer 2009; 9: 361-71. 
http://dx.doi.org/10.1038/nrc2628 
[11] Harrison ML, Obermueller E, Maisey NR, et al. Tumor 
necrosis factor as a new target for renal cell carcinoma: two 
sequential phase II trials of infliximab at standard and high 
dose. J Clin Oncol 2007; 25: 4542-9. 
http://dx.doi.org/10.1200/JCO.2007.11.2136 
[12] Schmielau J, Finn OJ. Activated granulocytes and 
granulocyte-derived hydrogen peroxide are the underlying 
mechanism of suppression of t-cell function in advanced 
cancer patients. Cancer Res 2001; 61: 4756-60. 
[13] Rotondo R, Barisione G, Mastracci L, et al. IL-8 induces 
exocytosis of arginase 1 by neutrophil polymorphonuclears in 
nonsmall cell lung cancer. Int J Cancer 2009; 125: 887-93. 
http://dx.doi.org/10.1002/ijc.24448 
[14] Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing 
myeloid suppressor cells in renal cell carcinoma patients: a 
mechanism of tumor evasion. Cancer Res 2005; 65: 3044-8. 
[15] Jodele S, Chantrain CF, Blavier L, et al. The contribution of 
bone marrow-derived cells to the tumor vasculature in 
neuroblastoma is matrix metalloproteinase-9 dependent. 
Cancer Res 2005; 65: 3200-8. 
[16] Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial 
steps of ovarian cancer cell metastasis are mediated by 
MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest 
2008; 118: 1367-79. 
http://dx.doi.org/10.1172/JCI33775 
[17] Scapini P, Morini M, Tecchio C, et al. CXCL1/macrophage 
inflammatory protein-2-induced angiogenesis in vivo is 
mediated by neutrophil-derived vascular endothelial growth 
factor-A. J Immunol 2004; 172: 5034-40. 
http://dx.doi.org/10.4049/jimmunol.172.8.5034 
[18] Hasenclever D, Diehl V. A prognostic score for advanced 
Hodgkin's disease. International Prognostic Factors Project 
on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 
1506-14. 
http://dx.doi.org/10.1056/NEJM199811193392104 
[19] Alvaro-Naranjo T, Lejeune M, Salvadó-Usach MT, et al. 
Tumor-infiltrating cells as a prognostic factor in Hodgkin's 
lymphoma: a quantitative tissue microarray study in a large 
retrospective cohort of 267 patients. Leuk Lymphoma 2005; 
46: 1581-91. 
http://dx.doi.org/10.1080/10428190500220654 
[20] Schreck S, Friebel D, Buettner M, et al. Prognostic impact of 
tumour-infiltrating Th2 and regulatory T cells in classical 
Hodgkin lymphoma. Hematol Oncol 2009; 27: 31-9. 
http://dx.doi.org/10.1002/hon.878 
[21] Skinnider BF, Mak TW. The role of cytokines in classical 
Hodgkin lymphoma. Blood 2002; 99: 4283-97. 
http://dx.doi.org/10.1182/blood-2002-01-0099 
[22] Foss HD, Herbst H, Gottstein S, Demel G, Araujó I, Stein H. 
Interleukin-8 in Hodgkin's disease: preferential expression by 
reactive cells and association with neutrophil density. Am J 
Pathol 1996; 148: 1229-36. 
[23] Koh YW, Kang HJ, Park C, et al. Prognostic significance of 
the ratio of absolute neutrophil count to absolute lymphocyte 
count in classic Hodgkin lymphoma. Am J Clin Pathol 2012; 
138: 846-54.  
http://dx.doi.org/10.1309/AJCPO46GFKGNXCBR 
[24] Lai GG, Lim ST, Tao M, Chan A, Li H, Quek R. Late-onset 
neutropenia following RCHOP chemotherapy in diffuse large 
B-cell lymphoma. Am J Hematol 2009; 84: 414-7.  
http://dx.doi.org/10.1002/ajh.21420 
[25] Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. 
Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits 
the constitutive nuclear factor {kappa}B signaling pathway in 
non-Hodgkin's lymphoma B-cell lines: Role in sensitization to 
chemotherapeutic drug-induced apoptosis. Cancer Res 
2005; 65: 264-76. 
[26] Alas S, Bonavida B. Rituximab inactivates signal transducer 
and activation of transcription 3 (STAT3) activity in B non-
Hodgkin's lymphoma through inhibition of the interleukin 10 
NLR and Hematological Malignancies Global Journal of Hematology and Blood Transfusion, 2016, Vol. 3, No. 1    15 
autocrine/paracrine loop and down regulation of Bcl-2 and 
sensitization of cytotoxic drugs. Cancer Res 2001; 61: 5137-
44. 
[27] Troppan K, Deutsch A, Gerger A, et al. The derived 
neutrophil to lymphocyte ratio is an independent prognostic 
factor in patients with diffuse large B-cell lymphoma. Br J 
Cancer 2014; 110: 369-74. 
http://dx.doi.org/10.1038/bjc.2013.763 
[28] Keam B, Ha H, Kim TM, et al. Neutrophil to lymphocyte ratio 
improves prognostic prediction of International Prognostic 
Index for patients with diffuse large B-cell lymphoma treated 
with rituximab, cyclophosphamide, doxorubicin, vincristine 
and prednisone. Leuk Lymphoma 2015; 56: 2032-8. 
http://dx.doi.org/10.3109/10428194.2014.982642 
[29] Chang C, Wu SY, Kang YW, et al. High levels of regulatory T 
cells in blood are a poor prognostic factor in patients with 
diffuse large B-cell lymphoma. Am J Clin Pathol 2015; 144: 
935-44. 
http://dx.doi.org/10.1309/AJCPUJGMVV6ZF4GG 
[30] Ho CL, Lu CS, Chen JH, Chen YG, Huang TC, Wu YY. 
Neutrophil/lymphocyte ratio, lymphocyte/monocyte ratio, and 
absolute lymphocyte count/absolute monocyte count 
prognostic score in diffuse large B-cell lymphoma: Useful 
prognostic tools in the Rituximab era. Medicine (Baltimore) 
2015; 94: e993. 
http://dx.doi.org/10.1097/MD.0000000000000993 
[31] Melchardt T, Troppan K, Weiss L, et al. Independent 
prognostic value of serum markers in diffuse large B-cell 
lymphoma in the era of the NCCN-IPI. J Natl Compr Canc 
Netw 2015; 13: 1501-8. 
[32] Bladé J, Rosiñol L, Cibeira MT. Prognostic factors for 
multiple myeloma in the era of novel agents. Ann Oncol 
2008; 19(Suppl 7): vii117-20. 
http://dx.doi.org/10.1093/annonc/mdn437 
[33] Greipp PR, San Miguel J, Durie BG, et al. International 
staging system for multiple myeloma. J Clin Oncol 2005; 23: 
3412-20. 
http://dx.doi.org/10.1200/JCO.2005.04.242 
[34] Neben K, Jauch A, Bertsch U, et al. Combining information 
regarding chromosomal aberrations t(4;14) and del(17p13) 
with the International Staging System classification allows 
stratification of myeloma patients undergoing autologous 
stem cell transplantation. Haematologica 2010; 95: 1150-7. 
http://dx.doi.org/10.3324/haematol.2009.016436 
[35] Avet-Loiseau H, Durie BG, Cavo M, et al. Combining 
fluorescent in situ hybridization data with ISS staging 
improves risk assessment in myeloma: an International 
Myeloma Working Group collaborative project. Leukemia 
2013; 27: 711-7. 
http://dx.doi.org/10.1038/leu.2012.282 
[36] Moreau P, Cavo M, Sonneveld P, et al. Combination of 
international scoring system 3, high lactate dehydrogenase, 
and t(4;14) and/or del(17p) identifies patients with multiple 
myeloma (MM) treated with front-line autologous stem-cell 
transplantation at high risk of early MM progression-related 
death. J Clin Oncol: Off J Am Soc Clin Oncol 2014; 32: 2173-
80. 
http://dx.doi.org/10.1200/JCO.2013.53.0329 
[37] Kelkitli E, Atay H, Çilingir F, et al. Predicting survival for 
multiple myeloma patients using baseline 
neutrophil/lymphocyte ratio. Ann Hematol 2014; 93: 841-6. 
http://dx.doi.org/10.1007/s00277-013-1978-8 
[38] Romano A, Parrinello NL, Consoli ML, et al. Neutrophil to 
lymphocyte ratio improves the risk assessment of ISS 
staging in newly diagnosed MM patients treated upfront with 
novel agents. Ann Hematol 2015; 94: 1875-83. 
http://dx.doi.org/10.1007/s00277-015-2462-4 
[39] Beltran BE, Aguilar C, Quinoñes P, et al. The neutrophil-to-
lymphocyte ratio is an independent prognostic factor in 
patients with peripheral T-cell lymphoma, unspecified. Leuk 
Lymphoma 2015; 19: 1-5. 
http://dx.doi.org/10.3109/10428194.2015.1045897 
 
Received on 17-12-2015 Accepted on 08-01-2016 Published on 20-01-2016 
 
http://dx.doi.org/10.15379/2408-9877.2016.03.01.03 
© 2016 Burak Uz; Licensee Cosmos Scholars Publishing House. 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, 
provided the work is properly cited. 
 
